T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody
M Pulé, S Onuoha, AM Neves, M Ferrari… - US Patent …, 2024 - Google Patents
The present invention provides antibodies and polyclonal antibody preparations which bind
the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor …
the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor …
Anti TRBC1 antigen binding domains
S Cordoba, S Thomas, S Onuoha, R Jha… - US Patent …, 2022 - Google Patents
The present disclosure relates to anti-TRBC1 antigen binding domains characterized by the
sequences of the variable chains. The CDRs sequences of the variable chains are:(VH …
sequences of the variable chains. The CDRs sequences of the variable chains are:(VH …
Methods
M Pulé, P Maciocia - US Patent App. 17/832,307, 2023 - Google Patents
G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer
involving compounds serving as markers for tumor, cancer, neoplasia, eg cellular …
involving compounds serving as markers for tumor, cancer, neoplasia, eg cellular …
Multifunctional molecules that bind to calreticulin and uses thereof
A Loew, I Lamberto, JL Herrmann… - US Patent App. 16 …, 2021 - Google Patents
2021-05-03 Assigned to ELSTAR THERAPEUTICS, INC. reassignment ELSTAR
THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …
THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …
Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
M Pulé, S Cordoba, M Stavrou, V Peddareddigari… - 2020 - Google Patents
EP3662055A1 - Cells expressing a chimeric antigen receptor or engineered tcr and
comprising a nucleotide sequence which is selectively expressed - Google Patents …
comprising a nucleotide sequence which is selectively expressed - Google Patents …